SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 17 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Plum Acquisition Corp. IV. (NASDAQ: PLMK) Signs LOI With American Critical Resources to Advance U.S. Energy and Critical Minerals Supply
Plum Acquisition (NASDAQ: PLMK) announced it has entered into a non-binding letter of intent with American Critical Resources, a…
-
Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Completes 2025 Field Program at Atikokan REE Property
Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
A recent report from India is a stark reminder of ricin’s accessibility and the pressing…